Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

The Lancet Neurology

Volumn 11, Issue 5, 2012, Pages 405-413

  Färkkilä, Markus ^a   Diener, Hans Christoph ^b   Géraud, Gilles ^c   Láinez, Miguel ^d   Schoenen, Jean ^e   Harner, Nadja ^f   Pilgrim, Alison ^g   Reuter, Uwe ^h  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c CHU RANGUEIL   (France)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f FGK Clinical Research   (Germany)

^g NONE   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LASMIDITAN; PLACEBO;

ACUTE MIGRAINE; ADULT; AGED; ANALGESIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE AURA; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THERAPY EFFECT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859812075     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70047-9     Document Type: Article

References (23)

1. World Health Report 2001 2001, WHO, World Health Organization, Geneva.
2. Lipton RB, Buse DC, Serrano D, Ng-Mak DS, Pearlman SH, Reed M Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention study (P1342). Eur J Neurol 2011, 18(suppl 2):66-343.
3. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002, 22:633-658.
4. Tepper SJ, Millson D Safety profile of the triptans. Expert Opin Drug Saf 2003, 2:123-132.
5. MaasenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998, 98:25-30.
6. Gallagher RM, Kunkel R Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003, 43:36-43.
7. Neeb L, Meents J, Reuter U 5-HT1F receptor agonists: a new treatment option for migraine attacks?. Neurotherapeutics 2010, 7:176-182.
8. Adham N, Bard JA, Zgombick JM, et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology 1997, 36:569-576.
9. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010, 30:1159-1169.
10. Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia 2010, 30:1170-1178.
11. Pilgrim AJ, Dussault B, Rupniak N, et al. COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia 2009, 29(suppl 1):24-25.
12. International Classification of Headache Disorders: 2nd Edition. Cephalalgia 2004, 24(suppl 1):1-160.
13. Liefaard L, Drenth H-J, Pilgrim AJ, et al. Prediction of therapeutically effective dose of COL-144 based on relationship between plasma concentrations and headache response (poster). Cephalalgia 2009, 29(suppl 1):24.
14. Nam JM A simple approximation for calculating sample sizes for detecting linear trend in proportions. Biometrics 1987, 43:701-705.
15. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 2001, 358:1230-1234.
16. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996, 50:219-223.
17. Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Arch Pharmacol 2005, 371:178-184.
18. Dodick DW, Martin V Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004, 24:417-424.
19. Loder L Triptan therapy in migraine. N Engl J Med 2010, 363:63-70.
20. Bruinvels AT, Landwehrmeyer B, Gustafson EL, et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 1994, 33:367-386.
21. Ahn S-K, Khalmuratova R, Jeon S-Y, et al. Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei. Neurosci Lett 2009, 465:151-156.
22. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008, 372:2115-2123.
23. Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011, 31:573-584.